Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Next Previous
Trial Profile

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Dec 2025 According to a Clarity pharmaceuticals media release, announce the acceptance of an abstract from this study led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026, Europe's biggest urological conference, to be held 13-16 March 2026 in London, UK[2].
  • 14 Oct 2025 According to a Clarity pharmaceuticals media release, full analysis of all data generated in the Co-PSMA trial is underway, and results of this study will be presented at an upcoming international conference.
  • 14 Oct 2025 Primary endpoint (Detection rate of lesions per participants, between 64Cu-SAR-bisPSMA and 68Ga PSMA-11 PET/CT) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top